Cite
HARVARD Citation
Bixia, T. et al. (n.d.). 152P A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma. Immuno-oncology technology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Bixia, T. et al. (n.d.). 152P A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma. Immuno-oncology technology. p. . [Online].